TD Private Client Wealth’s Corcept Therapeutics CORT Stock Holding History

TD Private Client Wealth’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.1K	Sell	77 -102	-57%	-$3.81K	﹤0.01%	1241
2025 Q4	$6.23K	Buy	179 +92	+106%	+$7.23K	﹤0.01%	1134
2025 Q3	$7.23K	Hold	87	–	–	﹤0.01%	1096
2025 Q2	$6.39K	Buy	+87	New	+$6.31K	﹤0.01%	1094
2023 Q1	–	Sell	-595	Closed	-$12.1K	–	1245
2022 Q4	$12.1K	Sell	595 -25	-4%	-$627	﹤0.01%	981
2022 Q3	$15.9K	Sell	620 -19	-3%	-$508	﹤0.01%	947
2022 Q2	$15.2K	Sell	639 -69	-10%	-$1.5K	﹤0.01%	955
2022 Q1	$15.9K	Buy	+708	New	+$15.1K	﹤0.01%	977

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

TD Private Client Wealth's CORT Position: Q1 2026 in Review

TD Private Client Wealth reduced its Corcept Therapeutics (CORT) stake by 57% in Q1 2026, selling an estimated $3.81K and leaving 77 shares worth $3.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1241.

TD Private Client Wealth first reported a position in CORT in Q1 2022 and has held it in 8 quarters since. The position peaked at $15.9K in Q1 2022. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

TD Private Client Wealth held 77 shares of Corcept Therapeutics worth $3.1K as of Q1 2026.
TD Private Client Wealth sold 102 Corcept Therapeutics shares in Q1 2026, an estimated $3.81K.
Corcept Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q1 2026, its #1241 holding.
TD Private Client Wealth first reported a position in Corcept Therapeutics in Q1 2022 and has held it in 8 quarters since.
TD Private Client Wealth's Corcept Therapeutics position peaked at $15.9K in Q1 2022.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.